Amgen (AMGN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $6.29
- EPS estimate
- $5.62
- EPS surprise
- +11.97%
- Revenue surprise
- +6.66%
- Revenue
- $10.1B
- Revenue estimate
- $9.4B
- Reported
- Aug 4, 2026
Amgen reported Q2 2026 results on August 4, 2026. Earnings per share came in at $6.29, ahead of the $5.62 estimate by 11.97%. Revenue was $10.1 billion, 6.66% above the $9.4 billion consensus. Compared with Q2 2025, EPS rose about 4.5% from $6.02 and revenue rose about 10% from $9.2 billion. EPS also rose from $5.15 in Q1 2026.
The longer record shows steady growth. Annual EPS rose every year in the table, from $17.69 in 2022 to $18.65 in 2023, $19.82 in 2024 and $21.85 in 2025. Revenue grew faster, about 40%, from $26.3 billion in 2022 to $36.8 billion in 2025. The first half of 2026 adds up to $11.44 per share, about 5% more than the same period a year earlier. Q2 2026 set the highs here for both EPS and revenue and was the first above $10 billion. Over the last 20 quarters, Amgen topped the EPS estimate 18 times. The two misses, in Q4 2022 and Q2 2024, were each under 0.3%.
Amgen reported Q3 results between October 30 and November 4 in each of the past five years. That points to late October or early November 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $5.62 | $6.29 | +11.97% | $10.1B | SEC |
| Q1 2026 | Apr 30, 2026 | $4.77 | $5.15 | +8.04% | $8.6B | SEC |
| Q4 2025 | Feb 3, 2026 | $4.73 | $5.29 | +11.74% | $9.9B | SEC |
| Q3 2025 | Nov 4, 2025 | $5.02 | $5.64 | +12.37% | $9.6B | SEC |
| Q2 2025 | Aug 5, 2025 | $5.28 | $6.02 | +13.98% | $9.2B | SEC |
| Q1 2025 | May 1, 2025 | $4.27 | $4.90 | +14.76% | $8.1B | SEC |
| Q4 2024 | Feb 4, 2025 | $5.09 | $5.31 | +4.31% | $9.1B | SEC |
| Q3 2024 | Oct 30, 2024 | $5.27 | $5.58 | +5.79% | $8.5B | SEC |
| Q2 2024 | Aug 6, 2024 | $4.98 | $4.97 | −0.29% | $8.4B | SEC |
| Q1 2024 | May 2, 2024 | $3.88 | $3.96 | +2.09% | $7.4B | SEC |
| Q4 2023 | Feb 6, 2024 | $4.59 | $4.71 | +2.58% | $8.2B | SEC |
| Q3 2023 | Oct 31, 2023 | $4.67 | $4.96 | +6.23% | $6.9B | SEC |
| Q2 2023 | Aug 3, 2023 | $4.49 | $5.00 | +11.29% | $7.0B | SEC |
| Q1 2023 | Apr 27, 2023 | $3.85 | $3.98 | +3.45% | $6.1B | SEC |
| Q4 2022 | Jan 31, 2023 | $4.10 | $4.09 | −0.17% | $6.8B | SEC |
| Q3 2022 | Nov 3, 2022 | $4.47 | $4.70 | +5.22% | $6.7B | SEC |
| Q2 2022 | Aug 4, 2022 | $4.43 | $4.65 | +4.90% | $6.6B | SEC |
| Q1 2022 | Apr 27, 2022 | $4.10 | $4.25 | +3.78% | $6.2B | SEC |
| Q4 2021 | Feb 7, 2022 | $4.04 | $4.36 | +8.04% | $6.8B | SEC |
| Q3 2021 | Nov 2, 2021 | $4.29 | $4.67 | +8.73% | $6.7B | SEC |
Quarterly revenue
Frequently asked questions
When did Amgen (AMGN) last report earnings?
Amgen last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did AMGN beat earnings estimates?
Yes. Amgen reported EPS of $6.29 for Q2 2026 against a $5.62 estimate — a 11.97% beat.
How much revenue did AMGN report last quarter?
Amgen reported $10.1B in revenue for Q2 2026, against a consensus estimate of $9.4B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.